VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PGNY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PGNYProgyny, Inc.
$34.84$2.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPGNYBalance Sheet

Progyny, Inc. (PGNY) Balance Sheet

9Y historyFree accessUpdated daily

The balance sheet remains conservatively leveraged with a debt-to-equity ratio of 0.06 and cash of $152.6M, though equity growth has slowed amid the client loss.

Income StatementBalance SheetCash FlowRatios

PGNY Balance Sheet

Annual statement

PGNY Balance Sheet

Progyny, Inc. (PGNY) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets464.4M551.77M472.72M640.41M433.86M258.54M190.22M132.44M24.54M16.77M
Cash & Short-Term Investments195.59M310.1M227.95M371.09M189.3M119.42M109.3M80.38M127K4.69M
Cash Only116.82M112.24M162.31M97.3M120.08M91.41M70.31M80.38M127K4.69M
Short-Term Investments78.77M197.86M65.64M273.79M69.22M28M38.99M000
Accounts Receivable249.18M220.29M235.32M241.87M240.07M134.56M75.66M47.06M23.32M11.37M
Days Sales Outstanding67.5262.3973.5981.1111.3598.180.0874.7880.7785.44
Inventory0000000000
Days Inventory Outstanding----------
Other Current Assets19.63M21.39M9.44M27.45M4.49M000200K0
Total Non-Current Assets211.39M190.66M134.38M116.21M109.13M99.53M63.7M17.99M16.79M18.19M
Property, Plant & Equipment73.12M54.92M29.63M27.82M15.27M12.83M12.07M3.08M776K597K
Fixed Asset Turnover23.28x23.47x39.39x39.13x51.52x39.01x28.58x74.50x135.82x81.38x
Goodwill19.83M19.98M15.53M11.88M11.88M11.88M11.88M11.88M11.88M11.88M
Intangible Assets5.53M6.22M1.3M099K599K1.21M2.38M3.86M5.34M
Long-Term Investments925K000000000
Other Non-Current Assets19.83M16.54M2.98M3.4M3.99M2.94M573K652K272K372K
Total Assets675.79M742.43M607.1M756.62M542.99M358.06M253.93M150.43M41.32M34.96M
Asset Turnover1.89x1.74x1.92x1.44x1.45x1.40x1.36x1.53x2.55x1.39x
Asset Growth %-3.03%22.29%-19.76%39.34%51.64%41.01%68.8%264.04%18.2%-
Total Current Liabilities240.04M202.39M168.63M185.95M159.54M98.82M77.79M36.16M30.2M17.77M
Accounts Payable148M124.07M95.1M125.43M109.29M61.4M43.51M19.39M15.58M5.13M
Days Payables Outstanding52.846.0137.9853.8764.3857.6957.838.4266.1445.47
Short-Term Debt00000000253K3.56M
Deferred Revenue (Current)000000009.39M7.13M
Other Current Liabilities023.48M19.87M13.05M8.88M12.26M7.69M13M11.64M6.73M
Current Ratio1.93x2.73x2.80x3.44x2.72x2.62x2.45x3.66x0.81x0.94x
Quick Ratio1.93x2.73x2.80x3.44x2.72x2.62x2.45x3.66x0.81x0.94x
Cash Conversion Cycle14.72---------
Total Non-Current Liabilities21.73M24M16.41M17.24M6.48M7.42M9.19M0106.24M6.5M
Long-Term Debt0000000001.63M
Capital Lease Obligations91.47M24M16.41M17.24M6.48M7.42M8.32M000
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities000000876K004.87M
Total Liabilities261.76M226.39M185.04M203.19M166.02M106.24M86.98M36.16M30.2M24.27M
Total Debt21.73M27.73M19.27M19.39M7.71M8.65M9.55M0253K5.19M
Net Debt-95.09M-84.51M-143.04M-77.91M-112.36M-82.76M-60.76M-80.38M126K497K
Debt / Equity0.05x0.05x0.05x0.04x0.02x0.03x0.06x-0.02x0.49x
Debt / EBITDA0.16x0.31x0.27x0.30x0.31x0.26x0.93x---
Net Debt / EBITDA-0.71x-0.94x-2.03x-1.21x-4.51x-2.46x-5.93x-6.81x--
Interest Coverage-------166.84x-6.95x-14.87x
Total Equity414.03M516.04M422.06M553.43M376.97M251.82M166.95M114.27M11.12M10.69M
Equity Growth %-21.75%22.27%-23.74%46.81%49.7%50.84%46.1%927.43%4.04%-
Book Value per Share5.105.774.425.503.772.511.691.370.141.88
Total Shareholders' Equity414.03M516.04M422.06M553.43M376.97M251.82M166.95M114.27M11.12M10.69M
Common Stock9K9K9K9K9K9K9K8K1K1K
Retained Earnings281.36M202.83M144.31M89.97M27.93M-2.42M-68.19M-113.48M-104.85M-104.56M
Treasury Stock-621.04M-388.07M-303.89M-1.01M-1.01M-1.01M-1.01M-1.01M-884K0
Accumulated OCI173K498K39K2.82M501K-93K1K-150.43M-483K-83K
Minority Interest0000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Client concentration and utilization volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Equity Growth Slows Amid Client Loss

Total equity rose to $453.3M in Q2 2026 from $422.1M a year earlier, but the pace of growth decelerated sharply, reflecting the reported loss of a major enterprise client and a maturing revenue base.

The balance sheet is still expanding, but the rate of equity accumulation has slowed from 8.1% year-over-year in Q2 2025 to 7.4% in Q2 2026, per reported figures. This deceleration aligns with the revenue slowdown and suggests that the company's ability to generate retained earnings is being tested. Investors should monitor whether the equity growth can be sustained without the contribution from the lost client.

Minimal Leverage Masks Refinancing Risk

Total debt of $27.0M in Q2 2026 represents a debt-to-equity ratio of just 0.06, per financial statements, indicating minimal reliance on borrowed capital, but the slight increase in debt over the past year warrants monitoring.

The debt level is negligible relative to equity, and the company appears to have ample capacity to service its obligations. However, the gradual rise in total debt from $19.3M in Q4 2024 to $27.0M in Q2 2026, as reported, may indicate a strategic shift toward modest leverage. Given the asset-light model and strong cash position, this is not a concern, but investors should watch for any acceleration in borrowing that could signal a change in capital allocation philosophy.

Asset-Light Model with Rising Intangibles

PP&E of $42.0M in Q2 2026 is only 5.9% of total assets, per reported data, underscoring the asset-light nature of the business, while goodwill of $19.9M remains modest but has grown from $11.9M in Q1 2024.

The balance sheet is dominated by current assets, particularly cash and receivables, which is typical for a service-based healthcare administrator. The increase in goodwill, though small in absolute terms, suggests that acquisitions have been part of the growth strategy. The low PP&E intensity implies minimal capital expenditure requirements, which supports the strong free cash flow conversion observed in the cash flow statement.

Retained Earnings Drive Equity Quality

Retained earnings reached $255.1M in Q2 2026, up from $144.3M in Q4 2024, per balance sheet data, indicating that equity growth is primarily funded by accumulated profits rather than external financing.

The steady increase in retained earnings, despite the deceleration in revenue growth, suggests that the company is generating consistent profitability. However, the prior cash flow analysis noted that stock-based compensation exceeded operating income in Q2 2026, which implies that a portion of the equity growth may be attributable to non-cash charges. Investors should adjust for SBC to assess the true economic earnings power.

Strong Liquidity Buffer Despite Cash Dip

Cash and equivalents of $152.6M in Q2 2026, combined with a current ratio of 2.14, per reported figures, provide a solid liquidity cushion, though cash has declined from $162.3M in Q4 2024.

The current ratio remains above 2.0, indicating that short-term obligations are well covered. The decline in cash from Q4 2024 to Q2 2026, as reported, may be partly due to share repurchases and the timing of claims payments. Given the asset-light model and minimal debt, the liquidity position appears adequate to absorb operational shocks, but the loss of a major client could pressure cash flows if working capital dynamics turn unfavorable.

SBC and Client Losses Distort Balance Sheet

Stock-based compensation of $40.2M in Q2 2026 exceeded operating income, per financials, suggesting that reported equity growth is partly driven by non-cash charges, while the loss of a major client may impair future asset growth.

The balance sheet appears healthy on the surface, but the heavy reliance on SBC to fund equity expansion raises questions about the quality of earnings. Additionally, the reported loss of a significant enterprise client could lead to a reduction in receivables and deferred revenue, potentially shrinking the asset base in coming quarters. Investors should monitor the trajectory of goodwill and intangibles for any impairment risk, especially if the client loss leads to a reassessment of future cash flows.

PGNY — Frequently Asked Questions

Quick answers to the most common questions about buying PGNY stock.

What are the total assets of Progyny, Inc. (PGNY)?

As of 2025, Progyny, Inc. (PGNY) had total assets of $742.4M including $551.8M in current assets.

How much debt does Progyny, Inc. (PGNY) have?

Progyny, Inc. (PGNY) carries total debt of $27.7M, offset by $310.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Progyny, Inc.?

Progyny, Inc. (PGNY) has total shareholders' equity (book value) of $516.0M ($5.77 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Progyny, Inc.'s current ratio and liquidity?

Progyny, Inc. (PGNY) reported a current ratio of 2.73x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.